echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Into China three years or twice face the price of waist cut! How does Pfizer's pillar products break the siege?

    Into China three years or twice face the price of waist cut! How does Pfizer's pillar products break the siege?

    • Last Update: 2020-07-31
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    One arthritis patient said in the group.
    after the 2019 national health care negotiations, many patients in the country are using the fennel tothecloth tablets announced that the price reduction was included in the health insurance, the original purchase of generic drugs from Bangladesh patients after the national organization of health care negotiations.
    at the same time, in the past less than a year, three domestic generic drugs were approved for the market, but relative to the original research drug into the price of health insurance, patients issued the above-mentioned sigh.
    and on July 6th, the genericdrug, which is in the middle of the day, announced another price cut in Yunnan and Sichuan.
    01 "Negotiating only 200 pieces" tothetabibum is the world's first small molecule-targeted JAK kinase inhibitor for rheumatoid arthritis, originally developed by Pfizer, which was approved by the U.S. FDA in November 2012 for the treatment of adult patients with moderate to severe rheumatoid arthritis, and subsequently expanded a variety of adaptations such as psoriasis arthritis, ulcerative colitis and other adaptations.
    , too, the company's fifth-largest product, reported global sales of $2.242 billion in 2019, up 26 percent from a year earlier, and a 7 percent increase in the first quarter of this year.
    in China, tofatible was approved in 2017 and is currently only used to treat adult patients with rheumatoid arthritis.
    negotiated access to the Category B health care catalog in 2019.
    Pfizer is expanding its domestic certification for plaque psoriasis, active psoriasis arthritis, and juvenile iexclusiveidarthritis.
    as for tofateb sales in China, Minnet data show that its 2019 public medical institutions terminal sales of 43.62 million yuan, up 423.02 percent year-on-year, approved for three years, the product is in a period of rapid growth.
    it's worth noting that two years after China's approval, Tofateb negotiated a price cut into the health care catalog, and within two years it was hit by generic drugs, and even more embarrassingly, Tofatib was included in the third batch of national collection sonthis this year, into China for three years or faced two price cuts.
    Tofatib has become a clear case of china's pharmaceutical market reform in recent years.
    For Pfizer, the still growing TOP5 product in China and around the world will face a stormy price cut and a rapid siege of generics.
    first, in terms of price, Pfizer was priced at about 1990 yuan per bottle (5mg x 28), and two years later, in the 2019 health-care negotiations, Pfizer included the tofatib on health care by cutting prices.
    also negotiated during the same period are two rheumatoid arthritis biologics , Adamu monotonica and Inphyse.
    Pfizer chose to keep it a secret in its negotiation of a price for health care.
    but the current major terminals have made price adjustments, patients in the hospital to buy the price is 980 yuan (there are also patients said 960 yuan), as to the price of health insurance payment is not yet accurate news.
    it was clear that in the health care negotiations, Thefatibu made a 50 00% discount.
    and on July 6th, Zhengda Tianqing adjusted the price of its generic drugs in Yunnan and Sichuan from 780 yuan to 750 yuan, a small drop in price.
    is precisely because of this relative to the original study of 75% discount price, triggered the first patient's sigh.
    it is worth noting that before the health care negotiations, the price of Zhengda Qing was 1250 yuan, about 60% of the original research.
    health insurance negotiations directly reduce the price difference between primary research and generic drugs in patients' minds.
    a patient in the Beijing area said: Pfizer's Tofateb 960 yuan a box, a month to use two boxes of a total of 1960 yuan, through the medical insurance reimbursement after the price is lower, Beijing after the medical insurance reimbursement to pay the cost of the individual only less than 600 yuan per month, is the day qing to fatib 798 yuan a box, a month to use two boxes of a total of 1596 yuan, the same access to health insurance, but most of the hospitals do not have medicine.
    in the eyes of patients, the original research and imitation of the price after reimbursement is not much difference, and zhengda sunny approval time is less than a year, coupled with the impact of the epidemic, the current hospital admission effect is not ideal (there may be regional differences).
    apparently, the generics have also suffered a wave of embarrassment after the health-care negotiations.
    02 approved for three years, two waist cuts? But in the Chinese market, where the external environment is changing dramatically, the current pattern may soon be broken, and companies will not sit back.
    in 2020, Tofateb will face the "1-plus-three" market pattern and the baptism of volume procurement.
    following the approval of the first counterfeit in September 2019, The imitation of Qilu and Collon has also been approved, the "1-3" market pattern has been formed, but the current price pattern will be maintained for less than a year.
    Qilu's Tofatib was approved at the end of October 2019, Jiangsu, Ningxia, Hainan and other places of tender information show that the price of 880 yuan, between Zhengda Qing and Pfizer, about 10% after the original negotiations.
    and colum pharmaceuticals approved a generic drug a week ago, there is no price information.
    in the face of negotiations to reduce the price of the original research products, Zhengda Qing in addition to the market price reduction in the hospital, according to some patients, early this year, in Henan, Jilin and other places in the pharmacy also carried out drug-giving activities.
    E drug manager on July 8 dialed a pharmacy in Zhengzhou City, according to the other side, the current generic drug gift activities are still in progress: "buy two give one, a total of only 1572 yuan, and support health insurance payment."
    " equivalent to a bottle of 524 yuan price, about the original research level of 50%, Zhengda Qing in the outside market once again opened the price difference.
    in addition, the above three generic drugs are approved in four types of generic drugs, as if through consistency evaluation, which means that all three have received this year's third batch of national collection of tickets.
    in addition, the domestic application / as if applied for the product consistency evaluation of the product is also Yangzijiang, Chengdu Bete, stone medicine, such as More than ten enterprises.
    's patent was originally due to expire in 2020, but it was pulled into the war with generics early because of the success of the patent.
    in the current price pattern, according to the previous two harvest decline, the second half of this year, the competition is more adequate to the tofatibs may have another price cut.
    for Pfizer, the TOP5 product in the volume, in China in the three years after approval faced two major heavyweight policies and genericdrugs, ushered in a number of price cuts, will have a significant impact on its sales.
    just down the health care bureau's negotiating table, the field ushered in generic / similar drug competition, followed by several domestic pharmaceutical companies with the same volume procurement arena, such a scenario with the health care negotiations and the volume procurement process accelerated, encryption, will not only Pfizer need to face.
    AstraZeneca's Gifitini and Tegrillo, and the new-key Azasinthin, among others, have experienced or are about to experience two big-weight policy killings.
    before the publication of the third batch of national belt procurement varieties, there have been industry forecasts that biosimilar drugs will be included in the collection, and most of these varieties of the original research have experienced health insurance negotiations.
    , although the final prediction was unsuccessful, the possibility of biosimilars being included in the collection remains.
    at present, only four of the current domestic approved biological similar drugs, but in two years, Adamu monotag, belavbead monotonica, qutodremonotin, lituximatoritus and other large global varieties will usher in full competition in the country, and sales and degree of competition is also included in the importance of one of the important criteria for the purchase of the belt.
    in addition to some in recent years into China's liver disease, diabetes and other fields of products there are similar risks.
    thus, future market access for pharmaceutical companies may need to seriously consider both policy gates and market strategies such as pricing.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.